SCHEMBL21756558

SCHEMBL21756558

CCN1CCN(c2ccc([N+](=O)[O-])c(Nc3ncc(/C=C(\F)c4c(Cl)c(OC)cc(OC)c4Cl)cn3)c2C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 8/20 0.39
▸ FGFR4 P22455 6/20 0.39
▸ ALDH1A1 P00352 6/20 0.39
▸ MAPT P10636 4/20 0.37
▸ LMNA P02545 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ PDGFRA P16234 3/20 0.37
▸ PDGFRB P09619 1/20 0.37
▸ WDR5 P61964 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ FGFR2 P21802 3/20 0.35
▸ FGFR3 P22607 3/20 0.35
▸ JAK2 O60674 2/20 0.35
▸ ABL1 P00519 2/20 0.35
▸ INSR P06213 2/20 0.35
▸ LCK P06239 2/20 0.35
▸ FYN P06241 2/20 0.35
▸ YES1 P07947 2/20 0.35
▸ LYN P07948 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21386697 0.87 PDGFRA (0.39) FGFR1FGFR4MAPTPDGFRAPDGFRB
SCHEMBL23365599 0.85 FGFR4 (0.42) FGFR1FGFR4ALDH1A1LMNAPDGFRA
SCHEMBL21756515 0.83 FGFR4 (0.52) FGFR1FGFR4FGFR2FGFR3
SCHEMBL21756516 0.81 FGFR1 (0.36) FGFR1FGFR4ALDH1A1LMNAPDGFRA
SCHEMBL21386670 0.79 FGFR4 (0.47) FGFR1FGFR4FGFR2FGFR3CYP2D6
SCHEMBL21386682 0.78 EGFR (0.42) FGFR1FGFR4SRC
SCHEMBL21756559 0.77 FGFR1 (0.50) FGFR1FGFR4ALDH1A1MAPTKMT2A
SCHEMBL21756620 0.76 MAPT (0.40) ALDH1A1MAPTLMNASMN1; SMN2WDR5
SCHEMBL21386604 0.76 FGFR4 (0.37) FGFR1FGFR4FGFR2FGFR3
SCHEMBL21756524 0.74 FGFR4 (0.68) FGFR1FGFR4FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2021-05-18 — — US disclosed
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2020-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof FGFR4, FGFR1, FGFR2 FGFR1 2/4885FGFR4 1/4885ALDH1A1 993/4885
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF FGFR4, FGFR1, FGFR2 FGFR1 2/4885FGFR4 1/4885ALDH1A1 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback